Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Ludwig Institute for Cancer Research
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00199862
First received: September 13, 2005
Last updated: March 28, 2014
Last verified: March 2014

September 13, 2005
March 28, 2014
February 2004
June 2015   (final data collection date for primary outcome measure)
  • To determine and quantify tumor uptake of radiolabeled antibody from measurements with: [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • PET imaging/Dosimetry [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • Autoradiographs - tumor or biopsy samples [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • Ex vivo radioactivity estimates - tumor, normal tissue and serum samples [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • Toxicity defined by NCI Common Toxicity Criteria [ Time Frame: Until end of study ] [ Designated as safety issue: Yes ]
  • • To determine and quantify tumor uptake of radiolabeled antibody from measurements with:
  • -PET imaging/Dosimetry
  • -Autoradiographs – tumor or biopsy samples
  • -Ex vivo radioactivity estimates – tumor, normal tissue and serum samples
  • • Toxicity defined by NCI Common Toxicity Criteria
Complete list of historical versions of study NCT00199862 on ClinicalTrials.gov Archive Site
  • Serum radioactivity, volume of distribution, and half-life following IV and IA 124I-huA33 [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • HAHA levels - measured by plasmon resonance surface (Biacore®) assay [ Time Frame: Until end of study ] [ Designated as safety issue: No ]
  • • Serum radioactivity, volume of distribution, and half-life following IV 124I-
  • huA33
  • • HAHA levels - measured by plasmon resonance surface (Biacore®) assay
Not Provided
Not Provided
 
Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
A Pilot Study of Radioimmunodetection of 124-Iodine-labeled Humanized A33 Antibody (124I-huA33) in Patients With Colorectal Cancer

The purpose of this study is to determine whether our drug, 124I-huA33, can safely detect colorectal cancer.

This is an open-label, pilot study of a single 4mCi-10mCi/10mg IV dose of 124I-huA33 in patients with colorectal cancer. Patients will be studied with 124I-huA33 positron-emission tomography (PET), and in the subset of patients scheduled for surgery, based on clinical indications, ex vivo quantitation of tumor uptake will also be performed. Patients will receive a single intravenous or intraarterial infusion of 4 mCi-10mCi /10mg 124I-huA33 in 5-30ml of 5% human serum albumin (HSA), over 5-10 minutes. Patient will either receive the 124I-huA33 intravenously (IV) or intraarterially (IA) to determine if there is an advantage of the IV vs the IA route. Following injection with 124I-huA33, on study days 2, 3, and/ or 4, patients will have the option to receive up to 2g/1kg of Immune Globulin (IVIG).

Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV or IA infusion, on day 2, 3, and/ or 4, and before and after the PET scan on the day of surgery or last imaging day (day 8 + 3). Patients scheduled for surgery will undergo a PET scan of the abdomen and pelvis 1-6 hours prior to surgery.

In those patients undergoing surgery, surgery (or biopsy) will be scheduled to occur day 8 (± 3 days) days after administration of 124I-huA33. Biopsy sites may include tumor, tumor bed, regional nodes, portal, suprapancreatic, celiac nodes and the retroperitoneum. Tumor and normal tissue obtained at surgery (or biopsy), and serum will be measured for estimation of percent-injected dose per gram of tumor, normal liver, and serum. Tissue samples will be obtained for autoradiography and immunohistochemistry as an additional assessment of tumor targeting.

Blood samples to determine immunogenicity will be taken at baseline and at 4 weeks.

Toxicity assessments will be made throughout the study period.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Colorectal Neoplasms
  • Colorectal Cancer
  • Colorectal Tumor
  • COlorectal Carcinoma
Drug: Iodine-124 labeled humanized A33 (antibody)
Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
Experimental: Radio-labeled huA33 Antibody

Patients will receive a single I-V infusion of 4mCi-10mCi/10mg 124I-huA33 in 5-30 mL of 5% human serum albumin (HAS) in normal saline, over 5 minutes-4 hours. Patients will be studied with 124I-huA33 positron-emission tomography (PET) and ex-vivo quantitation of tumor uptake .

Blood samples will be obtained for pharmacokinetic analysis at 5, 15, 60, and 120 minutes after completion of IV, on and before or after PET scanning on subsequent days.

Surgery (or biopsy) will be scheduled to occur 8- 10 days after administration of 124I-huA33. The 8-10 day imaging session will be scheduled for the morning of surgery or biopsy, approximately 1-6 hours before the procedure.

Intervention: Drug: Iodine-124 labeled humanized A33 (antibody)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Primary or metastatic colorectal carcinoma, histologically confirmed at Memorial Sloan-Kettering Cancer Center (MSKCC).
  • Patients must be candidates for clinically indicated surgery/biopsy for primary/metastatic colorectal cancer
  • Expected survival of at least 3 months.
  • Karnofsky performance status ≥ 70 (ECOG 0 or 1).
  • The following laboratory results within the last 2 weeks prior to study day 1:

Absolute neutrophil count (ANC) ≥ 1.5 x 109/L Platelet count ≥ 75 x 109/L Serum bilirubin ≤ 2.5 mg/dL Serum creatinine ≤ 2.0 mg/dL White Blood Count (WBC) ≥ 3,000/mm3 Age ≥ 18 years. Children of all ages are not included as colon cancer is extremely rare in children.

  • Women of childbearing potential with confirmed negative pregnancy test on the day of administration of study agent.
  • Before any trial-specific procedures or treatment can be performed, the patient or patient's legally authorized guardian or representative must give witnessed written informed consent for participation in the tria

Exclusion Criteria:

  • Clinically significant cardiac disease (New York Heart Association Class III/IV).
  • Active CNS tumor involvement. Previous treatment with A33 or its fragment and/or a positive test for huA33 HAHA.
  • Lack of availability for immunological and clinical follow-up assessments.
  • Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
  • Women who are pregnant or breast-feeding.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00199862
03-124
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Ludwig Institute for Cancer Research
Principal Investigator: Steven M Larson, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP